Drug Approval | August 12, 2021
Human studies begin on AI discovered COVID-19 treatment with up to 97% effectiveness
A treatment to prevent extreme symptoms and cut hospitalisation
A treatment to prevent extreme symptoms and cut hospitalisation
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Company working on COVID vaccine INO 4800
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
The goal for the project is the identification and optimization of anti-viral compounds.
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Advances deployment of mRNA technology across vaccines and therapeutics development
Subscribe To Our Newsletter & Stay Updated
